上海精缮生物科技

Accurate Biosciences is a Shanghai-based biotechnology company specializing in the development of next-generation gene and cell therapies. Founded in 2020 by leading experts in genome editing, the company leverages advanced CRISPR/Cas9, base editing, and prime editing technologies to address unmet medical needs in genetic diseases. Their primary focus includes hematological disorders such as Hemophilia B and Beta-thalassemia, utilizing both in vivo and ex vivo approaches. Accurate Biosciences aims to provide curative treatments through precise genomic modifications with high efficiency and minimal off-target effects. The company has secured significant venture capital funding from prominent investors to advance its proprietary technology platforms and clinical pipeline.